Expertise in
27
conditions

Dr. Sunil S. Dhawan

Dermatology
Office
2557 Mowry Ave Ste 25, 
Fremont, CA 
Accepting New Patients
Referral required
Before you request
Expertise in
27
conditions
Office
2557 Mowry Ave Ste 25, 
Fremont, CA 

Overview

Sunil Dhawan is a Dermatologist practicing medicine in Fremont, California.

Dr. Dhawan is highly rated in 27 conditions, according to our data. His clinical expertise encompasses Acne, Nummular Eczema, Comedones, and Plaque Psoriasis.

He is actively involved in clinical research, co-authoring 26 peer reviewed articles and participating in 28 clinical trials. Dr. Dhawan is currently accepting new patients.

Specialties

Dermatology

Licenses

Dermatology in CA

Hospital Affiliations

Washington Hospital

Languages Spoken

English
Hindi
Punjabi

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Chinese Community Health
  • HMO
  • MEDICARE SNP
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

HealthPartners
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
LA Care
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Nippon Life
  • INSURANCE PLAN
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Santa Clara Family Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
Sutter Health
  • HMO
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Valley Health
  • HMO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 27 Less Insurance Carriers -

Locations

Office
2557 Mowry Ave Ste 25, Fremont, CA 94538

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

25 Clinical Trials

A Multicenter, Randomized, Double Blind, Vehicle-controlled, Phase 2 Efficacy and Safety Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Patients With Non-Gorlin High Frequency BCC
A Multicenter, Randomized, Double Blind, Vehicle-controlled, Phase 2 Efficacy and Safety Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Patients With Non-Gorlin High Frequency BCC
Enrollment Status: Terminated
Publish Date: July 21, 2026
Intervention Type: Drug
Study Drug: Patidegib
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
Enrollment Status: Completed
Publish Date: April 07, 2026
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Longitudinal Observational Study of Patients Undergoing Therapy for Immune-Mediated Inflammatory Skin Conditions
A Longitudinal Observational Study of Patients Undergoing Therapy for Immune-Mediated Inflammatory Skin Conditions
Enrollment Status: Active_not_recruiting
Publish Date: March 20, 2026
A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Phase 2 Dose-Response Study to Determine Safety and Effectiveness of Two Concentrations of NFX-179 Gel in Subjects With Cutaneous Neurofibromas
A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Phase 2 Dose-Response Study to Determine Safety and Effectiveness of Two Concentrations of NFX-179 Gel in Subjects With Cutaneous Neurofibromas
Enrollment Status: Completed
Publish Date: February 17, 2026
Intervention Type: Drug
Study Drug: NFX-179
Study Phase: Phase 2
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Completed
Publish Date: November 05, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
Skin Fluorescent Imaging (SFI) System in Patients With Nevi
Skin Fluorescent Imaging (SFI) System in Patients With Nevi
Enrollment Status: Completed
Publish Date: August 07, 2025
Intervention Type: Diagnostic test
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Trial to Evaluate the Efficacy and Safety of ASLAN004 in Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Trial to Evaluate the Efficacy and Safety of ASLAN004 in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: April 26, 2024
Intervention Type: Drug, Biological
Study Drug: ASLAN004
Study Phase: Phase 2
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Psoriasis
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Psoriasis
Enrollment Status: Completed
Publish Date: February 20, 2024
Intervention Type: Drug
Study Drug: LY3471851
Study Phase: Phase 1
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Atopic Dermatitis
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: February 20, 2024
Intervention Type: Drug
Study Drug: NKTR-358
Study Phase: Phase 1
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug
Study Drug: Lebrikizumab
Study Phase: Phase 3
View 9 Less Clinical Trials

26 Total Publications

Impact of Oral DFD-29, a Low-Dose Formulation of Minocycline, on Quality of Life in Patients with Rosacea: Results of Two Phase 3 Randomized Controlled Trials.
Impact of Oral DFD-29, a Low-Dose Formulation of Minocycline, on Quality of Life in Patients with Rosacea: Results of Two Phase 3 Randomized Controlled Trials.
Journal: The Journal of clinical and aesthetic dermatology
Published: December 19, 2025
Similar Doctors
Expertise in
14
conditions
Expertise in
14
conditions
Referral may be required
Before you request

Stanford University

875 Blake Wilbur Dr, 
Palo Alto, CA 
 (13.4 miles away)
650-498-6000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Youn-hee Kim is a Dermatologist practicing medicine in Palo Alto, California. Dr. Kim is highly rated in 14 conditions, according to our data. Her clinical expertise encompasses Mycosis Fungoides, T-Cell Lymphoma, Cutaneous T-Cell Lymphoma (CTCL), and Sezary Syndrome. Dr. Kim is currently accepting new patients.

Expertise in
16
conditions
Expertise in
16
conditions
Referral required
Before you request

Stanford University Medical Center

450 Broadway St, 
Redwood City, CA 
 (13.0 miles away)
650-723-6316
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Dr. David Fiorentino, MD is a Dermatologist in Redwood City, CA and has over 24 years of experience in the medical field. He graduated from Stanford University in 1998. He is affiliated with Stanford Health Care. Dr. Fiorentino is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Dermatomyositis, Systemic Sclerosis (SSc), Scleroderma, and Calcinosis. Dr. Fiorentino is board certified in Board Certification: American Board Of Dermatology, Dermatology (2002). Dr. Fiorentino is currently accepting new patients.

Expertise in
97
conditions
Expertise in
97
conditions
Referral may be required
Before you request

Stanford Hospital And Clinics

965 High St, 
Palo Alto, CA 
 (12.4 miles away)
650-723-4000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Kerri Rieger is a Dermatologist practicing medicine in Palo Alto, California. Dr. Rieger is highly rated in 97 conditions, according to our data. Her clinical expertise encompasses Basal Cell Skin Cancer, Mycosis Fungoides, Melanoma, and Epidermolysis Bullosa with Pyloric Atresia. Dr. Rieger is currently accepting new patients.

Frequently Asked Questions about Dr. Sunil S. Dhawan

How do I make an appointment with Dr. Sunil S. Dhawan?

You can book an appointment with Dr. Sunil S. Dhawan by calling their office at 510-797-4111. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Sunil S. Dhawan a top-rated expert for Acne?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Sunil S. Dhawan is classified as an Distinguished expert for Acne, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Sunil S. Dhawan specialize in?

While Dr. Sunil S. Dhawan is a Dermatology, they have specific expertise in Acne, Nummular Eczema, and Comedones. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Dermatology.

Does Dr. Sunil S. Dhawan participate in research or clinical trials?

Yes. Dr. Sunil S. Dhawan has published 26 articles and abstracts on conditions like Acne. You can view a list of Dr. Sunil S. Dhawan's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Sunil S. Dhawan accept my insurance?

Dr. Sunil S. Dhawan accepts most major insurance plans, including Aetna and Alignment Health Plan. We recommend calling the office directly at 510-797-4111 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Dhawan's expertise for a condition
ConditionClose
    View All 24 Advanced Conditions
    View All 87 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile